SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings.

Jones, F; Hu, Y; Coates, A (2022) The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings. Antibiotics (Basel), 11 (3). p. 323. ISSN 2079-6382 https://doi.org/10.3390/antibiotics11030323
SGUL Authors: Coates, Anthony Robert Milnes

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (977kB) | Preview

Abstract

Pseudomonas aeruginosa is a Gram-negative bacterium which is capable of developing a high level of antibiotic resistance. It has been placed on the WHO's critical priority pathogen list and it is commonly found in ventilator-associated pneumonia infections, blood stream infections and other largely hospital-acquired illnesses. These infections are difficult to effectively treat due to their increasing antibiotic resistance and as such patients are often treated with antibiotic combination regimens. METHODS: We conducted a systematic search with screening criteria using the Ovid search engine and the Embase, Ovid Medline, and APA PsycInfo databases. RESULTS: It was found that in many cases the combination therapies were able to match or outperform the monotherapies and none performed noticeably worse than the monotherapies. However, the clinical studies were mostly small, only a few were prospective randomized clinical trials and statistical significance was lacking. CONCLUSIONS: It was concluded that combination therapies have a place in the treatment of these highly resistant bacteria and, in some cases, there is some evidence to suggest that they provide a more effective treatment than monotherapies.

Item Type: Article
Additional Information: Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Keywords: ESBLs, Pseudomonas aeruginosa, beta-lactams, carbapenems, combination therapy, extensively drug resistant (XDR), multidrug resistant (MDR)
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Antibiotics (Basel)
ISSN: 2079-6382
Language: eng
Dates:
DateEvent
28 February 2022Published
24 February 2022Accepted
Publisher License: Creative Commons: Attribution 4.0
PubMed ID: 35326786
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114230
Publisher's version: https://doi.org/10.3390/antibiotics11030323

Actions (login required)

Edit Item Edit Item